Clovis Oncology, Inc.(NASDAQ : CLVS)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||0.26%||178.60||0.7%||$1354.05m|
|MRK||Merck & Co., Inc.||1.88%||94.39||0.7%||$1234.84m|
|LLY||Eli Lilly & Co.||1.33%||331.54||1.1%||$1039.83m|
|BMY||Bristol-Myers Squibb Co.||0.94%||76.67||1.0%||$1000.78m|
|TPTX||Turning Point Therapeutics, Inc.||-0.11%||75.07||0.0%||$199.07m|
|HZNP||Horizon Therapeutics Plc||-0.01%||82.76||5.4%||$174.09m|
|MRTX||Mirati Therapeutics, Inc.||1.56%||73.09||1.6%||$153.18m|
|ALNY||Alnylam Pharmaceuticals, Inc.||0.45%||151.40||8.1%||$150.98m|
|NVO||Novo Nordisk A/S||-0.92%||110.22||0.1%||$147.01m|
Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.